About

Shu-Hua Wang, MD, is a board-certified infectious disease physician and a professor at The Ohio State University Wexner Medical Center. She specializes in diagnosing and treating complex infectious conditions, with particular expertise in tuberculosis and antimicrobial-resistant infections such as MRSA. Dr. Wang collaborates with a multidisciplinary team to provide personalized, high-quality, and compassionate care to her patients. In addition to her clinical practice, she is dedicated to education and mentoring the next generation of healthcare providers. She serves as a clinical professor of Internal Medicine in the Division of Infectious Diseases at The Ohio State University College of Medicine. Her research interests include rapid TB diagnostic tests and the molecular epidemiology of MRSA. She has contributed to the field through publications in TB and MRSA, and she is involved in international projects related to Global One Health, TB, and antimicrobial resistance, particularly in Ethiopia, China, and Guatemala. Dr. Wang completed her medical education at the Medical College of Wisconsin and has undertaken fellowships in infectious disease at Tulane Medical Center, LSU Health Sciences Center, and the University of Wisconsin Hospitals and Clinics. She is a member of several professional organizations, including the Infectious Diseases Society of America and the International Union of Tuberculosis and Lung Disease.

Research topics

• Medicine
• Pediatrics
• Immunology
• Internal medicine
• Pathology

Selected publications

• The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity

  The Journal of Experimental Medicine · 2021 · 206 citations

  • Virology
  • Immunology
  • Biology

  N 6-methyladenosine (m6A) is the most prevalent posttranscriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate antiviral and antitumor immunity. However, whether and how m6A modifications affect NK cell immunity remain unknown. Here, we discover that YTHDF2, a well-known m6A reader, is upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection. Ythdf2 deficiency in NK cells impairs NK cell antitumor and antiviral activity in vivo. YTHDF2 maintains NK cell homeostasis and terminal maturation, correlating with modulating NK cell trafficking and regulating Eomes, respectively. YTHDF2 promotes NK cell effector function and is required for IL-15-mediated NK cell survival and proliferation by forming a STAT5-YTHDF2 positive feedback loop. Transcriptome-wide screening identifies Tardbp to be involved in cell proliferation or survival as a YTHDF2-binding target in NK cells. Collectively, we elucidate the biological roles of m6A modifications in NK cells and highlight a new direction to harness NK cell antitumor immunity.

  DOI

• Accuracy of the tuberculosis point-of-care Alere determine lipoarabinomannan antigen diagnostic test using α-mannosidase treated and untreated urine in a cohort of people living with HIV in Guatemala

  AIDS Research and Therapy · 2020 · 5 citations

  • Medicine
  • Immunology
  • Internal medicine

  BACKGROUND: Improved point-of-care diagnostic tests for tuberculosis (TB) in severe immune suppressed people living with HIV (PLWH) are needed to decrease morbidity and mortality outcomes. The aim of the study is to evaluate the performance of the lipoarabinomannan antigen test (LAM-test) with and without α-mannosidase pre-treated urine in a cohort of PLWH in primary care clinics in Guatemala. We further determined TB incidence, and mortality rates and its risk factors in PLWH with TB symptoms. METHODS: MTB/RIF (Xpert, Cepheid, Sunnyvale, CA, USA) results was used in the LAM-test diagnostic accuracy studies. Cox proportional hazards regression was used to study mortality predictors. RESULTS: The overall sensitivity of the LAM-test was of 56.1% with 95% CI of (43.3-68.3). There were no differences in the LAM-test sensitivity neither by hospital nor by CD4 T cell values. LAM-test sensitivity in PLWH with < 200 CD4 T cells/µl was of 62.2% (95% CI 46.5-76.2). There were no significant differences in sensitivity when comparing LAM-test results obtained from untreated vs. α-mannosidase treated urine [55.2% (95% CI 42.6-67.4) vs. 56.9% (95% CI 44-69.2), respectively]. TB incidence in our cohort was of 21.4/100 person years (PYs) (95% CI 16.6-27.6), and mortality rate was of 11.1/100 PYs (95% CI 8.2-15.0). Importantly, PLWH with a positive LAM-test result had an adjusted hazard ratio (aHR) of death of 1.98 (1.0-3.8) with a significant p value of 0.044 when compared to PLWH with a negative LAM-test result. CONCLUSIONS: In this study, α-mannosidase treatment of urine did not significantly increase the LAM-test performance, however; this needs to be further evaluated in a large-scale study due to our study limitations. Importantly, high rates of TB incidence and mortality were found, and a positive LAM-test result predicted mortality in PLWH with TB clinical symptoms.

  DOI

Frequent coauthors

• Joshua C. Cyktor

  4 shared

• Bridget Carruthers

  The Ohio State University

  4 shared

• Joanne Turner

  Milton Keynes Hospital

  4 shared

• Blanca I. Restrepo

  2 shared

• Samuel S. Stew

  Advisory Board Company (United States)

  2 shared

• Jordi B. Torrelles

  Texas Biomedical Research Institute

  1 shared

• Carlos Mejía-Villatoro

  Roosevelt Hospital

  1 shared

• Janet Ikeda

  San Francisco Department of Public Health

  1 shared

Similar researchers at Ohio State University

• Guo-Liang Wangh-115
• Brad J. Bushmanh-101
• Christopher Hillh-97
• David Bromwichh-93
• K. Luan Phanh-92